Study: Covidien's stroke device beats standard therapy

In an independent study by the University of Edinburgh, Covidien's ($COV) Kendall SCD system decreased deep vein thrombosis by 29.9% in immobile stroke patients and reduced mortality risk by 14% compared to routine therapy. Kendall SCD is currently recommended only for stroke sufferers who can't tolerate blood-thinning injections, but the investigators say the device could save as many as 10,000 lives each year with wider use. More